LTZ Therapeutics, a Redwood Metropolis, CA- and Shenzen, China-based immunotherapy-focused biotech firm, closed its Collection A financing of over $20m.
This spherical, which introduced whole funding to roughly $50m, was led by new investor Lapam Capital with participation from GL Ventures, K2 Enterprise Companions and Shunwei Capital.
The corporate intends to make use of the funds to advance the event of its Myeloid Engager pipeline to deal with most cancers and autoimmune illnesses. Proceeds from the financing will probably be used to speed up growth of LTZ’s pipeline, supporting the corporate’s Investigational New Drug (IND) course of, initiating the Section 1 medical examine of LTZ’s lead asset LTZ-301 in addition to the IND-enabling work of its second asset, LTZ-232. LTZ Therapeutics may even use the brand new capital to additional advance different applications in discovery and to develop its workforce.
Led by Robert Li, Ph.D., Founder and CEO, LTZ Therapeutics is an immunotherapy-focused biotech firm pursuing the event of novel therapies, with its novel Myeloid Engager Platform, to enhance medical outcomes in sufferers with most cancers and autoimmune illnesses. With most important operations in Redwood Metropolis, California and Shenzhen, China in addition to a workforce out of Heidelberg Germany, LTZ is devoted to creating immunotherapies able to overcoming resistance and boosting anti-tumor immunity based mostly on reverse translational science and rising illness biology of tumor microenvironment.
FinSMEs
30/07/2024
